2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2771

Higher Incident Rates of Comorbidities in Patients with Psoriatic Arthritis (PsA) Compared to Controls

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2462

Higher Number of Tender Than Swollen Joint Count Is Associated to Higher Patient Reported Outcomes and Composite Scores As Well As Reduced Probability of Obtaining Remission: Results from a One-Year Follow-up Study of Established RA Patients Starting Bdmards

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2355

Histology of Bone Marrow Lesions in Osteoarthritis: A Systematic Literature Review

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2838

Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2256

Histopathologic Features and Tissue Interferon-Response Gene Scoring of Lesional Skin Samples for Diagnosis in Autoinflammatory Disorders

Innate Immunity and Rheumatic Disease - Poster II

9:00AM-11:00AM: Abstract Number: 2932

HLA-DR3 Restricted Response to Lupus-Related Auto-Antigen Smd: Autoreactive T Cells Are Inherent in Normal Immune Repertoires

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2933

HLA-DR3 Restricted T Cell Response to Smd and Ro60 Reveals Multiple Cross-Reactive Intra- and Inter-Molecular T Cell Epitopes: Unique Antigenic Structures of Lupus-Related Auto-Antigens and the Basis for B Cell Epitope Spreading

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2742

How Are Enthesitis, Dactylitis and Nail Involvement Measured and Reported in Recent Clinical Trials of Psoriatic Arthritis (PsA)? a Systematic Literature Review

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2682

How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2469

How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2412

Human Gut Microbial Species Correlate with Arthritis in the K/BxN Mouse Model

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2783

Human Mesenchymal Stem Cells from Different Tissues Exert Distinct Therapeutic Effect on Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 2562

Human Seroreactivity to Gut Microbiota Antigens in Rheumatoid Arthritis and Controls-Lack of Association with Rheumatoid Arthritis Autoantibodies

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2792

Hyperhomocysteinemia in SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2958

Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden

Vasculitis - Poster III: Rarer Vasculitides

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].